Acceleron Pharma (XLRN) 10-K2019 FY Annual report

Filed: 27 Feb 20, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: add, allosteric, androgen, Asunercept, background, BPCIA, brain, clerical, Cloud, coincide, concomitant, construed, cutoff, DOJ, EC, episode, evolution, expedient, fluctuate, fluctuation, Footnote, Fulcrum, IBR, implicit, incorrect, infrastructure, Inline, insolvency, interceded, JAK, JCC, Justice, kemal, legitimate, Logit, MAA, malik, mccourt, mitapivat, NaN, natriuretic, occasional, occupied, oLogit, Orchard, Organization, PKR, pronouncement, propeptide, pyruvate, quantitative, REBLOZYL, regression, residual, ruxolitinib, Sanofi, sBLA, skilled, slightly, smaller, social, software, stable, straight, stringent, subset, syndrome, taxonomy, TD, Thoracic, transitionary, variance, ZYNTEGLO

Removed: accept, accreted, alleviate, antagonist, assured, asymmetric, attest, BPCA, BPCI, collected, complying, concluding, confidence, confirm, deferral, depression, detected, disability, disabling, downstream, enactment, exceeding, expedited, eXtensible, functionality, GlaxoSmithKline, improving, ingredient, intervention, Language, lessee, live, lt, marker, moiety, neurodegenerative, onset, orthotic, painful, permanent, PREA, predicted, procedural, qualification, ready, reconciling, redemption, remedy, responsive, richard, roughly, route, send, skeletal, slated, subpopulation, surgical, systemic, threshold, tom, unapproved, undertaken, viral, writing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated XLRN transcripts

XLRN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:


(1)	Registration Statement (Form S-8 No. 333-192789) pertaining to the Acceleron Pharma Inc. 2003 Stock Option and Restricted Stock Plan and the Acceleron Pharma Inc. 2013 Equity Incentive Plan,


(2)	Registration Statement (Form S-8 No. 333-198259) pertaining to the Acceleron Pharma Inc. 2013 Employee Stock Purchase Plan and the Acceleron Pharma Inc. 2013 Equity Incentive Plan,


(3)	Registration Statement (Form S-8 No. 333-203354) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,


(4)	Registration Statement (Form S-8 No. 333-211867) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,


(5)	Registration Statement (Form S-8 No. 333-219661) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,


(6)	Registration Statement (Form S-3 No. 333-220522) of Acceleron Pharma Inc.,


(7)	Registration Statement (Form S-8 No. 333-223270) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan, and


(8)	Registration Statement (Form S-8 No. 333-229911) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan;

of our reports dated February 27, 2020, with respect to the consolidated financial statements of Acceleron Pharma Inc. and the effectiveness of internal control over financial reporting of Acceleron Pharma Inc. included in this Annual Report (Form 10-K) of Acceleron Pharma Inc. for the year ended December 31, 2019.



		/s/ Ernst & Young LLP

Boston, Massachusetts

February 27, 2020